GLP-1 compounding 2025 — the legal landscape after the shortage list.

Background: why compounding existed in the first place

Under section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies may compound drug products for an individually identified patient pursuant to a valid prescription. Section 503B authorizes registered outsourcing facilities to compound at larger scale without patient-specific prescriptions, subject to FDA inspection and current good manufacturing practice (CGMP) standards. Both pathways have always existed alongside the commercial drug supply chain. They are not in themselves loopholes.

Critically, both 503A and 503B compounders are generally prohibited from producing a drug that is "essentially a copy" of a commercially available FDA-approved product. The principal exception: when the FDA-approved product appears on the agency's official drug shortage list, compounders may produce essentially copies during the shortage period to mitigate patient access problems [FDA compounding policy].

Semaglutide (Ozempic, Wegovy) was placed on the FDA drug shortage list in 2022 amid unprecedented demand. Tirzepatide (Mounjaro, Zepbound) followed in 2023. For roughly two years, both molecules existed in a compounding gray zone where 503A pharmacies and 503B outsourcing facilities could legitimately produce versions of these molecules, sold predominantly through telehealth platforms at significantly lower prices than the branded products. By 2024, the compounded GLP-1 supply was a multi-billion-dollar parallel market.

February 2025: the shortage resolution

On February 21, 2025, FDA updated its drug shortage database and issued a formal Declaratory Order stating that the shortage of injectable semaglutide products had been resolved across all dose strengths [FDA shortage resolution Feb 2025]. The agency announced explicit enforcement-discretion windows during which compounders could wind down inventory:

• 503A state-licensed pharmacies: enforcement discretion through April 22, 2025.
• 503B registered outsourcing facilities: enforcement discretion through May 22, 2025.

After those dates, compounding "essentially a copy" of branded semaglutide became a violation of the FD&C Act regardless of prescription pattern or facility classification. Tirzepatide followed a parallel trajectory — its shortage status was resolved in October 2024 and the comparable wind-down periods completed in early 2025 [Buchanan Ingersoll briefing 2025].

The shortage list was the legal scaffolding on which the compounded GLP-1 market was built. When the FDA removed semaglutide from that list, the scaffolding came down — and most of the market built on it had to come down with it.

503A vs 503B — what the distinction means

For consumers trying to evaluate a compounded product, the distinction between 503A and 503B is more than legal trivia.

503A pharmacies are state-licensed and regulated primarily by state boards of pharmacy. They compound for an individually identified patient based on a valid prescription from a licensed prescriber. Quality oversight varies between states; FDA's direct authority is more limited than for manufacturers. The 503A pathway is designed for genuine personalization — a patient who cannot tolerate an ingredient in the commercial formulation, who needs a non-standard concentration, or whose dosing requires modification a manufacturer cannot accommodate.

503B outsourcing facilities register with FDA, are subject to CGMP standards comparable to those of branded manufacturers, and undergo direct FDA inspection. They can produce at scale and ship to clinicians without patient-specific prescriptions in some circumstances. Quality oversight is substantially more rigorous than 503A. The trade-off: 503Bs are more capital-intensive to operate and are correspondingly fewer in number.

During the shortage period, both pathways produced compounded GLP-1s. Much of the consumer-facing telehealth supply ran through 503A pharmacies. Some was produced by 503B facilities. The regulatory consequences of the February 2025 resolution applied to both, with the wind-down dates noted above.

The OFA lawsuit and the April ruling

On February 24, 2025 — three days after the FDA's Declaratory Order — the Outsourcing Facilities Association (OFA) filed suit in the U.S. District Court for the Northern District of Texas seeking to vacate the shortage resolution and reinstate the compounding pathway. The OFA argued that the FDA's determination was arbitrary and capricious and that real-world supply pressures had not in fact resolved [OFA complaint 2025].

On April 24, 2025, the district court denied the OFA's motion for a preliminary injunction [Court order April 2025]. The practical effect: FDA's enforcement-discretion timeline proceeded as published. After May 22, 2025, both 503A and 503B compounding of "essentially a copy" semaglutide became sanctionable. A parallel litigation track on tirzepatide had already produced a comparable result. The legal terrain that existed in 2024 — large-scale compounding of GLP-1s for the general weight-loss market under shortage-list authority — is effectively closed.

Where legitimate personalized compounding still exists

Compounding is not banned. The shortage-list pathway is closed, but the underlying 503A authority for genuine patient-specific personalization remains. Examples of where compounded GLP-1 products may still be produced legitimately:

• Documented allergy or intolerance to a commercial-product excipient. If a patient cannot tolerate a preservative or buffer system used in the commercial formulation, a 503A pharmacy can compound an alternative formulation pursuant to a prescription. This is a narrow indication and requires documentation that holds up to audit.
• Non-standard dose strengths or microdosing. If a clinician determines that a patient requires a dose not produced by the manufacturer — for example, micro-dosing for tolerability purposes — compounding remains an option in some interpretations of the rule, though the "essentially a copy" line is hotly litigated.
• Combination products. A compounded product combining semaglutide with another agent (B12, glycine, lipotropics) is not in itself "essentially a copy" — but the combination must serve a medical purpose, and the additives must be permitted in compounding. Many "combo GLP-1" products marketed in 2023–2024 are no longer defensible under the current enforcement posture.

The honest read: the legitimate personalized-compounding lane is narrower than the marketing of many telehealth platforms suggests. FDA has stated its enforcement priorities focus on products that are essentially copies of branded GLP-1s, products sold without legitimate prescriber oversight, and products with quality or safety problems [FDA compounder clarification 2025].

What patients on compounded GLP-1s should do

We are not your prescriber. With that caveat, a few practical observations for patients who started on a compounded product during the shortage period:

• Talk to your prescriber about transitioning to a commercial product. Branded semaglutide (Ozempic, Wegovy) and branded tirzepatide (Mounjaro, Zepbound) are generally accessible in 2025. Insurance coverage varies, and the cash-pay price gap relative to compounded products is real, but the supply problem that justified compounding is largely resolved.
• If you are continuing on a compounded product, ask where it is being made and under which authority. A legitimate 503B facility will tell you. A 503A pharmacy producing under a specific personalized exception will tell you. A platform that obfuscates the supplier is one to leave.
• Watch for dosing-unit confusion when switching between products. Compounded products are often supplied at different concentrations than commercial pens. The most common serious adverse events in the compounded market have been dosing errors on conversion. If you switch, walk through the new dosing with your prescriber.
• Understand the longer arc. The class is working as advertised — substantial weight loss, glycemic improvement, cardiometabolic risk reduction. What's worth getting right is sustainability. We have a related piece on maintenance, weight regain, and the protein-and-training case in GLP-1 weight regain; the comparative-efficacy story is in tirzepatide vs semaglutide; and the broader market context in the GLP-1 era. The forward look at retatrutide is in retatrutide, next-gen.